Aripiprazole for major depressive disorder

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 2 registered trials.

Why this status

  1. 19 Mar 2019: Trial registered, NCT03881449
  2. 4 Apr 2019: Trial started, NCT03881449

The trials

NCT03643159: A Trial to Measure the Difference in All-cause Hospitalizations for Participants Who Are Using Abilify MyCite Versus Virtual Matched Controls in Adults With Schizophrenia, Bipolar 1 Disorder, and Major Depressive Disorder

State
Stopped early
Phase
Phase 4
People
2 taking part
Started
28 Jun 2018
Primary completion
17 Oct 2018
Arms
Abilify MyCite
Results
Posted on the registry
  1. 28 Jun 2018: Trial started
  2. 22 Aug 2018: Trial registered
  3. 17 Oct 2018: Trial terminated
  4. 8 Nov 2019: Trial results posted

NCT03881449: DIMES - DIgital MEdicine Study for Adults With Schizophrenia, Bipolar I Disorder, or Major Depression Currently Using Aripiprazole

State
State not given
Phase
Phase 4
People
46 taking part
Started
4 Apr 2019
Primary completion
Jan 2021
Arms
ABILIFY MYCITE Group
Results
None posted
  1. 19 Mar 2019: Trial registered
  2. 4 Apr 2019: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Also known as Abilify, Abilify maintena, Abilify mycite, Abilify mycite kit, Aripiprex, Abilify MyCite - Digital Medicine System, Abilify MyCite®, Mezofy.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.